0001127602-23-004055.txt : 20230208 0001127602-23-004055.hdr.sgml : 20230208 20230208174232 ACCESSION NUMBER: 0001127602-23-004055 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230206 FILED AS OF DATE: 20230208 DATE AS OF CHANGE: 20230208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goyal Jaya CENTRAL INDEX KEY: 0001922548 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41374 FILM NUMBER: 23600263 MAIL ADDRESS: STREET 1: PEPGEN INC. STREET 2: 245 MAIN ST. CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PepGen Inc. CENTRAL INDEX KEY: 0001835597 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 MARINA PARK DRIVE, SUITE 900 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 703-456-8000 MAIL ADDRESS: STREET 1: 1 MARINA PARK DRIVE, SUITE 900 CITY: BOSTON STATE: MA ZIP: 02210 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-02-06 0001835597 PepGen Inc. PEPG 0001922548 Goyal Jaya 321 HARRISON AVE., 8TH FLOOR C/O PEPGEN INC. BOSTON MA 02118 1 EVP, Res. & Preclin. Dev. Common Stock 2023-02-06 4 M 0 1677 10.88 A 1677 D Common Stock 2023-02-06 4 S 0 1677 17.035 D 0 D Common Stock 2023-02-07 4 M 0 3679 10.88 A 3679 D Common Stock 2023-02-07 4 S 0 3679 17.182 D 0 D Common Stock 2023-02-08 4 M 0 644 10.88 A 644 D Common Stock 2023-02-08 4 S 0 644 17.00 D 0 D Stock Option (Right to Buy) 10.88 2023-02-06 4 M 0 1677 0 D 2031-11-10 Common Stock 1677 148519 D Stock Option (Right to Buy) 10.88 2023-02-07 4 M 0 3679 0 D 2031-11-10 Common Stock 3679 144840 D Stock Option (Right to Buy) 10.88 2023-02-08 4 M 0 644 0 D 2031-11-10 Common Stock 644 144196 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This stock option vests over four years following the vesting commencement date (October 15, 2021) with 25% of such shares vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in 36 equal monthly installments, subject to continued service through each vesting date. Executive Vice President, Research & Preclinical Development /s/ Noel Donnelly, as Attorney-in-Fact 2023-02-08